KURA Q1 2024 Earnings — Kura Oncology, Inc. Revenue & Financial Results | Market Cap Arena

KURAKura Oncology, Inc.

$815M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$234,000

Operating Income

-$54M

Net Income

-$50M

EPS (Diluted)

$-0.59

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$49M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$554M

Total Liabilities

$49M

Stockholders' Equity

$505M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$234,000	$0	—
Operating Income	-$54M	-$37M	-48.9%
Net Income	-$50M	-$34M	-45.4%